FDA's Advisory Committee to Review Claims That GlaxoSmithKline's Trelegy Ellipta Reduces MortalityThe Motley Fool • 02/21/20
GlaxoSmithKline Signs Potential $600 Million-Plus Cancer Immunotherapy Research-Partnership DealThe Motley Fool • 02/20/20
GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/06/20
GlaxoSmithKline's Priority Review For Cancer Drug Sets It Up For First Of A Kind FDA ApprovalSeeking Alpha • 01/28/20